Factors influencing the efficacy of initial adrenocorticotropic hormone therapy for infantile epileptic spasms syndrome.
10.7499/j.issn.1008-8830.2207096
- Author:
Xi HUANG
1
;
Jing PENG
1
;
Zou PAN
1
;
Pan PENG
1
;
Fang HE
1
;
Ci-Liu ZHANG
1
;
Chen CHEN
1
;
Fang-Yun LIU
1
;
Fei YIN
1
;
Lei-Lei MAO
1
Author Information
1. Department of Pediatric Neurology, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- Keywords:
Adrenocorticotropic hormone;
Efficacy;
Infant;
Infantile epileptic spasms syndrome;
Prognosis
- MeSH:
Child;
Humans;
Infant;
Adrenocorticotropic Hormone/therapeutic use*;
Spasms, Infantile/drug therapy*;
Treatment Outcome;
Seizures;
Electroencephalography/adverse effects*;
Spasm/drug therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(1):60-66
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the factors influencing the short-term (28 days) efficacy of initial adrenocorticotropic hormone (ACTH) therapy for infantile epileptic spasms syndrome (IESS), as well as the factors influencing recurrence and prognosis.
METHODS:The clinical data were collected from the children with IESS who received ACTH therapy for the first time in the Department of Pediatric Neurology, Xiangya Hospital of Central South University, from April 2008 to January 2018 and were followed up for ≥2 years. The multivariate logistic regression analysis was used to evaluate the factors influencing the short-term efficacy of ACTH therapy, recurrence, and long-term prognosis.
RESULTS:ACTH therapy achieved a control rate of seizures of 55.5% (111/200) on day 28 of treatment. Of the 111 children, 75 (67.6%) had no recurrence of seizures within 12 months of follow-up. The possibility of seizure control on day 28 of ACTH therapy in the children without focal seizures was 2.463 times that in those with focal seizures (P<0.05). The possibility of seizure control on day 28 of ACTH therapy in the children without hypsarrhythmia on electroencephalography on day 14 of ACTH therapy was 2.415 times that in those with hypsarrhythmia (P<0.05). The possibility of recurrence within 12 months after treatment was increased by 11.8% for every 1-month increase in the course of the disease (P<0.05). The possibility of moderate or severe developmental retardation or death in the children without seizure control after 28 days of ACTH therapy was 8.314 times that in those with seizure control (P<0.05). The possibility of moderate or severe developmental retardation or death in the children with structural etiology was 14.448 times that in those with unknown etiology (P<0.05).
CONCLUSIONS:Presence or absence of focal seizures and whether hypsarrhythmia disappears after 14 days of treatment can be used as predictors for the short-term efficacy of ACTH therapy, while the course of disease before treatment can be used as the predictor for recurrence after seizure control by ACTH therapy. The prognosis of IESS children is associated with etiology, and early control of seizures after ACTH therapy can improve long-term prognosis.
